The Riverside Technology Center in Cambridge, Mass., accommodates several biotech startups that could become the next Genzyme or Vertex Pharmaceuticals. Among these companies are Bluebird Bio, which is developing gene therapies for rare conditions, and Cerulean Pharma, which is working on a nanoparticle technology that can deliver drugs directly to tumors.

Related Summaries